Louise Birkedal Glenthj

List of Publications by Year in Descending Order

30 papers	340 citations	11 h-index	17 g-index
31 ext. papers	532 ext. citations	4.9 avg, IF	3.61 L-index

#	Paper	IF	Citations
30	Association of Structural Magnetic Resonance Imaging Measures With Psychosis Onset in Individuals at Clinical High Risk for Developing Psychosis: An ENIGMA Working Group Mega-analysis. *JAMA Psychiatry*, **2021**, 78, 753-766	14.5	17
29	Predictors of remission from the ultra-high risk state for psychosis. *Microbial Biotechnology*, **2021**, 15, 104-112	3.3	5
28	EPA guidance on treatment of negative symptoms in schizophrenia. *European Psychiatry*, **2021**, 64, e21	6	22
27	Obsessive-Compulsive Symptoms and Other Symptoms of the At-risk Mental State for Psychosis: A Network Perspective. *Schizophrenia Bulletin*, **2021**, 47, 1018-1028	1.3	2
26	Global fractional anisotropy predicts transition to psychosis after 12 months in individuals at ultra-high risk for psychosis. *Acta Psychiatrica Scandinavica*, **2021**, 144, 448-463	6.5	2
25	Changes in negative symptoms are linked to white matter changes in superior longitudinal fasciculus in individuals at ultra-high risk for psychosis. *Schizophrenia Research*, **2021**, 237, 192-201	3.6	0
24	EPA guidance on assessment of negative symptoms in schizophrenia. *European Psychiatry*, **2021**, 64, e23	6	28
23	Experiential negative symptoms are more predictive of real-life functional outcome than expressive negative symptoms in clinical high-risk states. *Schizophrenia Research*, **2020**, 218, 151-156	3.6	7
22	Basic symptoms influence real-life functioning and symptoms in individuals at high risk for psychosis. *Acta Psychiatrica Scandinavica*, **2020**, 141, 231-240	6.5	3
21	Supplementary data for a focused review and meta-analysis of H-MRS studies on cerebral glutamate and GABA levels in high-risk of psychosis states. *Data in Brief*, **2020**, 28, 104920	1.2	1
20	Cerebral glutamate and GABA levels in high-risk of psychosis states: A focused review and meta-analysis of H-MRS studies. *Schizophrenia Research*, **2020**, 215, 38-48	3.6	21
19	Cerebral Glutamate and Gamma-Aminobutyric Acid Levels in Individuals at Ultra-high Risk for Psychosis and the Association With Clinical Symptoms and Cognition. *Biological Psychiatry: Cognitive Neuroscience and Neuroimaging*, **2020**, 5, 569-579	3.4	7
18	Investigating Cognitive and Clinical Predictors of Real-Life Functioning, Functional Capacity, and Quality of Life in Individuals at Ultra-High Risk for Psychosis. *Schizophrenia Bulletin Open*, **2020**, 1,	2.2	3
17	Effectiveness of cognitive remediation in the ultra-high risk state for psychosis. *World Psychiatry*, **2020**, 19, 401-402	14.4	7
16	Cognitive remediation plus standard treatment versus standard treatment alone for individuals at ultra-high risk of developing psychosis: Results of the FOCUS randomised clinical trial. *Schizophrenia Research*, **2020**, 224, 151-158	3.6	10
15	No Effects of Cognitive Remediation on Cerebral White Matter in Individuals at Ultra-High Risk for Psychosis-A Randomized Clinical Trial. *Frontiers in Psychiatry*, **2020**, 11, 873	5	4
14	Baseline measures of cerebral glutamate and GABA levels in individuals at ultrahigh risk for psychosis: Implications for clinical outcome after 12 months. *European Psychiatry*, **2020**, 63, e83	6	3

13	Self-perceived cognitive impairments in psychosis ultra-high risk individuals: associations with objective cognitive deficits and functioning. *NPJ Schizophrenia*, **2020**, 6, 31	5.5	0
12	Assessing social skills in individuals at ultra-high risk for psychosis: Validation of the High Risk Social Challenge task (HiSoC). *Schizophrenia Research*, **2020**, 215, 365-370	3.6	4
11	Widespread higher fractional anisotropy associates to better cognitive functions in individuals at ultra-high risk for psychosis. *Human Brain Mapping*, **2019**, 40, 5185-5201	5.9	13
10	Emotion recognition latency, but not accuracy, relates to real life functioning in individuals at ultra-high risk for psychosis. *Schizophrenia Research*, **2019**, 210, 197-202	3.6	8
9	Validation of the MUSIC Model of Motivation Inventory for use with cognitive training for schizophrenia spectrum disorders: A multinational study. *Schizophrenia Research*, **2019**, 206, 142-148	3.6	5
8	Non-pharmacological modulation of cerebral white matter organization: A systematic review of non-psychiatric and psychiatric studies. *Neuroscience and Biobehavioral Reviews*, **2018**, 88, 84-97	9	6
7	Examining speed of processing of facial emotion recognition in individuals at ultra-high risk for psychosis: Associations with symptoms and cognition. *Schizophrenia Research*, **2018**, 195, 562-563	3.6	4
6	White matter maturation during 12 months in individuals at ultra-high-risk for psychosis. *Acta Psychiatrica Scandinavica*, **2018**, 137, 65-78	6.5	18
5	The effect of cognitive remediation in individuals at ultra-high risk for psychosis: a systematic review. *NPJ Schizophrenia*, **2017**, 3, 20	5.5	41
4	Negative symptoms mediate the relationship between neurocognition and function in individuals at ultrahigh risk for psychosis. *Acta Psychiatrica Scandinavica*, **2017**, 135, 250-258	6.5	17
3	Course of illness in a sample of patients diagnosed with a schizotypal disorder and treated in a specialized early intervention setting. Findings from the 3.5year follow-up of the OPUS II study. *Schizophrenia Research*, **2017**, 182, 24-30	3.6	13
2	Social cognition in patients at ultra-high risk for psychosis: What is the relation to social skills and functioning?. *Schizophrenia Research: Cognition*, **2016**, 5, 21-27	2.8	37
1	The FOCUS trial: cognitive remediation plus standard treatment versus standard treatment for patients at ultra-high risk for psychosis: study protocol for a randomised controlled trial. *Trials*, **2015**, 16, 25	2.8	32